Slides
Page 1
Investor Deck – Q1 FY26 July 30, 2025
Page 2
Safe Harbour Certain statements in this release concerning Sagility’ future growth prospects may be seen as forward - looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. Sagility does not undertake to update any such statement that may have been made from time to time by or on behalf of the company.. 2
Page 3
Q1 FY26 Performance Highlights Note: Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss). *Voluntary attrition (considering employees who were employees for more than 90 days) on an annualized basis ► Sagility has been named a Leader by Avasant in both - the Healthcare Payer Business Process Transformation 2025 RadarView and in the Clinical and Care Management Business Process Transformation 2025 RadarView ► Sagility won the ‘Most Preferred Workplace FY’26’ award by Marksmen Daily ₹ 15,389 million Organic Y-o-Y growth 17.9% 15.4 % at Constant Currency Y-o-Y growth 25.8% 23.1 % at Constant Currency ₹ 3,687 million Margin % 24.0% Y-o-Y growth % 26.5% ₹ 1,997 million Margin % 13.0% Y-o-Y growth % 38.0% Headcount 39,917 Attrition* 27.6% ► 17.9% Y-o-Y organic growth in Q1 FY26 driven by expansion from existing clients, while new wins are expected to further strengthen momentum in FY26 ► $32 M (potential steady state ACV) of new business & expansion won in Q1 FY26 ► Expansion and new SOWs from 18 existing clients in Q1 FY26 ► 4 new clients onboarded in Q1 ► Helping set-up a GCC for a client on a BOT model ► Operations remain robust, driven by strong performance across key metrics Clinicians & Technology heads 3200+
Page 4
Quarterly KPIs 4 Q1 FY26 Q4 FY25 Q1 FY25 YoY% Revenue from Operation (in INR Million) 15,389 15,685 12,233 25.8% Revenue by Vertical Split By Payer % 88.4% 89.7% 89.1% By Provider % 11.6% 10.3% 10.9% Growth in revenue from operation (%) 25.8% 22.2% 9.6% Adjusted EBITDA (in INR Million) 3,687 4,176 2,916 26.5% Adjusted EBITDA % 24.0% 26.6% 23.8% Adjusted PAT (in INR Million) 1,997 2,398 1,447 38.0% Adjusted PAT % 13.0% 15.3% 11.8% Total Number of Employees 39,917 39,409 35,858 11.3% Voluntary attrition rate* (%) 27.6% 32.5% 27.3% Note: Adjusted EBITDA represents EBITDA adjusted for earnouts payable under acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss). Voluntary attrition (considering employees who were employees for more than 90 days) on an annualized basis
Page 5
Annual KPIs 5 Q1 FY26 FY25 FY24 FY23 Number of Client groups* Active 77 75 44 35 Number of new client addition (Gross) 4 38 13 7 Delivery sites Number of delivery sites 33 33 30 27 New site addition (Gross) 2 10 4 2 TTM Jun 25 FY25 FY24 FY23 Client groups contribution to revenues Top 3 Client % 64.7% 66.2% 68.3% 72.4% Top 5 Client % 76.3% 77.9% 79.2% 80.6% Top 10 Client % 89.4% 90.5% 91.4% 90.7% Number of Million-dollar client groups Number of clients contributing more than US$20 million 7 7 5 4 Number of clients contributing to US$5 - US$20 million 6 6 7 7 Number of clients contributing to US$1 - US$5 million 17 12 12 12 Number of clients contributing less than US$1 million 47 50 20 12 * Client groups comprise client entities together with their affiliates.
Page 6
Market Updates 6 Market Changes Impact on Payer/ Provider Likely Impact on Sagility One Big Beautiful Bill – Cuts in Federal Medicaid Spending ► Revenue and margin are expected to be impacted for both Payers (due to drop in Medicaid Memberships and Medicaid funding cuts) and Providers (due to rising uninsured populations and lower reimbursement rates). ► Low exposure to Medicaid ( mid-single digits). Minimal impact of drop in Membership ► Increase in outsourcing by Payers & Providers to manage costs. Growing adoption of generative and agentic AI ► Deep healthcare expertise and the continued investments in building AI use cases in Healthcare, positions Sagility to deliver better business outcomes through lower cost and better end customer experience ► GenAI is gaining ground though Adoption is gradual. Emerging use cases. Domain expertise is the differentiator to driving meaningful outcomes Rising Medicare utilization rates impacting profitability ► This is expected to strain Payer margins; however, CMS increased MA payments by 5.06% for CY2026 ► Increase in outsourcing to manage costs better; however, pricing pressure to increase ► Strong tailwinds for higher outsourcing in clinical segment Tariffs ► Likely tariff driven increase in cost of imported medical equipment & Pharmaceuticals. Providers more exposed to Tariff risks than payers. ► No tangible impact
Page 7
Nurse Assist: Clinical reviews by enabling automated understanding and application of medical necessity guidelines across unstructured medical records Appeals assist: AI driven real-time support system that classifies appeals, extracts information, helps in decision making and that helps improve star ratings for payors and for providers, analyses denial reasons, checks medical records, determines medical necessities and generate appeal letters Engagement Audit and analytics: Using AI in engagement automation, audit and business intelligence solution for multi- channel interactions Contract Validation: AI based extraction and normalization of terms from complex payer- provider contracts In addition, we are building Agentic AI solutions to transform the way we run our business; Agentic AI collaborators will enhance our recruitment and training outcomes, lowering costs and helping us to serve our clients better Client Use cases: As on date, we have deployed roughly 18 AI based use-cases across 8 clients. We are also working on 15+ additional use cases that are relevant to the work that we currently do for our clients. Some examples below: Accelerating Value Delivery with AI 7
Page 8
Financial Highlights
Page 9
Q1 FY26 Financial Highlights 9 Strong Q1 FY26 Performance ₹ 15,389 million Organic Y-o-Y growth % 17.9% 15.4 % at Constant Currency Y-o-Y growth % 25.8% 23.1 % at Constant Currency ₹ 3,687 million Margin % 24.0% Y-o-Y growth % 26.5% ₹ 1,997 million Margin % 13.0% Y-o-Y growth % 38.0% ₹ 3,211 million Conversion % 90.2% DSO 75 days
Page 10
Quarter wise performance 33.5 * Q1 FY26 and Q4 FY25 Headcount includes BroadPath Headcount of 1,093 and 1,083 respectively (acquired in Q4 FY25) 36.5 36.6 35.0 35.8 38.3 39.6Headcount (‘000) 39.4 35.8 39.9 10 11,161 10,941 12,602 12,832 12,233 12.8% 11.5% 12.4% 12.9% 11.8% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0% - 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Revenue INR M Adjusted PAT % Headcount (‘000) Impact of seasonality on Q1 vs Q4 April 23 to June 24 12,233 13,250 14,531 15,685 15,389 11.8% 12.3% 18.1% 15.3% 13.0% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0% - 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Revenue INR M Adjusted PAT % April 24 to June 25 Increase in ETR in Q1 vs Q4
Page 11
Financial performance snapshot – Q1 FY26 Revenue (INR Million) Y-o-Y Q-o-Q 25.8% -1.9% Adjusted EBITDA* (INR Million) Y-o-Y Q-o-Q 26.5% -11.7% Adjusted PAT (INR Million) Y-o-Y Q-o-Q 38.0% -16.7% Revenue ($M) Y-o-Y Q-o-Q 23.1% -0.8% Adjusted EBITDA* ($M) Y-o-Y Q-o-Q 23.7% -10.7% Adjusted PAT ($M) Y-o-Y Q-o-Q 35.2% -15.8% 11*Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss). ₹12,233 ₹15,685 ₹15,389 Q1'25 Q4'25 Q1'26 $146.6 $181.8 $180.4 Q1'25 Q4'25 Q1'26 ₹1,447 ₹2,398 ₹1,997 Q1'25 Q4'25 Q1'26 ₹2,916 ₹4,176 ₹3,687 Q1'25 Q4'25 Q1'26 $34.9 $48.4 $43.2 Q1'25 Q4'25 Q1'26 $17.3 $27.8 $23.4 Q1'25 Q4'25 Q1'26
Page 12
Financial performance snapshot – Long Term Revenue (INR Million) FY25 YoY% TTM Jun YoY% 17.2% 21.1% Adjusted EBITDA * (INR Million) FY25 YoY% TTM Jun YoY% 28.4% 35.2% Adjusted PAT (INR Million) FY25 YoY% TTM Jun YoY% 37.5% 46.3% Revenue ($M) FY25 YoY% TTM Jun YoY% 14.9% 18.6% Adjusted EBITDA* ($M) FY25 YoY% TTM Jun YoY% 25.9% 32.5% Adjusted PAT ($M) FY25 YoY% TTM Jun YoY% 34.8% 43.4% 12*Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss). ₹11,436 ₹14,685 ₹11,432 ₹15,456 FY24 FY25 TTM Jun'24 TTM Jun'25 ₹47,536 ₹55,699 ₹48,608 ₹58,855 FY24 FY25 TTM Jun'24 TTM Jun'25 ₹5,896 ₹8,107 ₹5,919 ₹8,657 FY24 FY25 TTM Jun'24 TTM Jun'25 $572.9 $658.3 $583.8 $692.1 FY24 FY25 TTM Jun'24 TTM Jun'25 $137.8 $173.6 $137.3 $181.8 FY24 FY25 TTM Jun'24 TTM Jun'25 $71.1 $95.8 $71.1 $101.9 FY24 FY25 TTM Jun'24 TTM Jun'25
Page 13
Financial Indicators Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles asset s less current liabilities) Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent. Borrowing doesn’t include accrued interest 13 ₹21,678 ₹10,432 ₹7,894 1.9x 0.71x 0.51x - 0.50 1.00 1.50 2.00 ₹0 ₹5,000 ₹10,000 ₹15,000 ₹20,000 ₹25,000 FY'24 FY'25 TTM Jun'25 Net Debt Net Debt (in INR Million) Net Debt to Adjusted EBITDA 1.38 1.76 1.85 FY'24 FY'25 TTM Jun'25 Adjusted EPS (in INR) 87.2% 89.7% 90.2% 70.8% 80.5% 81.0% FY'24 FY'25 YTD Jun'25 Cash Conversion (%) OCF % FCF % 47% 55% 52% FY'24 FY'25 TTM Jun'25 Adjusted ROCE %
Page 14
Q1 FY26 Consolidated Profit and Loss 14 ► Q1 26 Organic Revenue at INR 14,429 Mn (YoY% 17.9% and 15.4% at constant currency YoY%) Amt in INR M Particulars Q1 FY26 Q4 FY25 Q1 FY25 YoY% QoQ% Revenue from Operation 15,389 15,685 12,233 25.8% -1.9% Employee benefits expense* 9,646 9,429 7,527 Other expenses^ 2,056 2,079 1,790 Adjusted EBITDA** 3,687 4,176 2,916 26.5% -11.7% Adjusted EBITDA % 24.0% 26.6% 23.8% Adjustments: M&A Earnouts 155 207 124 SAR (stock appreciation right) – Non Cash 71 104 852 Other Income^^ 50 101 35 Forex Gain / (Loss) 49 -135 209 Reported EBITDA 3,560 3,832 2,184 63.0% -7.1% Finance costs 274 298 374 Depreciation and amortisation 1,182 1,143 1,100 Profit Before Tax 2,104 2,390 710 196.3% -12.0% Tax Expenses 618 564 487 Reported Profit After Tax 1,486 1,826 223 566.4% -18.6% EPS 0.32 0.39 0.05 530.0% -18.6% Adjusted PAT 1,997 2,398 1,447 38.0% -16.7% Adjusted PAT % 13.0% 15.3% 11.8% Adjusted EPS (Rs) 0.43 0.51 0.33 30.5% -16.7% *Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), ^ Other expenses exclude forex loss. ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately. ** Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).
Page 15
Adjustments on EBITDA and PAT Adj EBITDA Bridge: Q1 FY26 Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax Adj B - Share based payment awards (non-cash expenses for the company and not tax deductible) Adj C - Amortization of intangible assets that got created due to carveout of healthcare business from HGS Adj PAT Bridge: Q1 FY26 INR Million INR Million 15 ₹1,486 ₹113 ₹71 ₹327 ₹1,997 Reported PAT Adj A Adj B Adj C Adjusted PAT ₹3,560 ₹155 ₹71 -₹99 ₹3,687 Reported EBITDA Adj A Adj B Other Income/Fx gain Adjusted EBITDA
Page 16
Go Forward Positions • Intangibles Amortisation (A) - Amortization of intangible assets that got created due to carveout of healthcare business from HGS • Intangibles Amortisation (B) - Amortisation for intangible assets acquired in relation to acquisitions (DCI, Birch and BroadPath) – Ends by FY33 16 Amt in INR M Particulars FY25 FY26 FY27 FY28 FY29 FY30 Closing Debt position 8,020 5,670 Debt Repayment 2,490 2,350 5,670 Interest Payment 751 535 285 Share based Payment awards 1,134 251 147 78 40 Earnouts Cost - DCI / Birch/ BroadPath 571 495 5 Intangibles Amortisation (A) 1,400 1,419 1,419 1,419 1,419 1,419 Intangibles Amortisation (B) 188 381 371 356 284 240
Page 17
Balance Sheet as on 30th June 25 17 Amt in INR M Particulars Jun 25 Mar 25 Property, plant and equipment 3,600 3,699 Capital-work-in-progress 19 0 Right-of-use assets 5,273 5,521 Goodwill 60,382 60,390 Other intangible assets 19,930 20,362 Trade receivables and Unbilled 12,994 12,668 Cash and cash equivalents 4,538 3,438 Deferred tax assets (net) 1,285 1,337 Other Assets 3,204 3,091 Total Assets 111,225 110,507 Equity 85,162 83,361 Borrowings 6,903 8,170 Lease liabilities 5,656 5,850 Trade payables 2,023 2,136 Deferred tax liabilities (net) 4,027 4,279 Other Liabilities 7,455 6,712 Total Liabilities 111,225 110,507
Page 18
Cash Flow – Q1 FY26 18 Amt in INR M Particulars Q1 FY26 FY25 Profit before tax for the period/ year 2,104 7,602 Adjustment for Non-Operating and Non-Cash items 1,552 6,982 Adjustment for working capital (254) (710) Income taxes paid (net of refunds) (191) (1,734) Net cash flows generated from operating activities (A) - OCF 3,211 12,141 Addition to Fixed Assets (326) (1,244) Free Cash flow (FCF) 2,885 10,896 Cash paid for M&A 0 (4,825) Pending Purchase consideration paid for healthcare business carveout 0 (3,756) Others 81 184 Net cash flows (used in) investing activities (B) (245) (9,642) Capital infused by promoter 0 3,708 Share Issue expense (paid)/ reimbursed 0 72 Repayment of Promoter borrowings (include Interest) (1,425) (4,567) Repayment of lease liabilities (include Interest) (456) (1,774) Net cash flows (used in) financing activities (C) (1,881) (2,561) Net increase/ (decrease) in cash and cash equivalents (A+B+C) 1,086 (62) Cash and cash equivalents at the beginning of the year/period 3,438 3,441 Effect of movement in exchange rates on cash and cash equivalents 15 58 Cash and cash equivalents at the end of the year/ period 4,538 3,438 Net cash flows generated from operating activities % (OCF on Reported EBITDA) 90.2% 89.7% Free Cash flow % (FCF on Reported EBITDA) 81.0% 80.5%
Page 19
P&L for Previous Quarters 19 Amt in INR M Particulars Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Revenue from Operation 11,161 10,941 12,602 12,832 12,233 13,250 14,531 15,685 15,389 Employee benefits expense* 6,361 6,674 7,912 7,925 7,527 7,912 8,415 9,429 9,646 Other expenses^ 1,881 1,795 1,789 1,764 1,790 1,874 1,988 2,079 2,056 Adjusted EBITDA** 2,919 2,472 2,901 3,143 2,916 3,465 4,127 4,176 3,687 Adjusted EBITDA % 26.2% 22.6% 23.0% 24.5% 23.8% 26.1% 28.4% 26.6% 24.0% Adjustments: M&A Earnouts 282 132 71 70 124 120 120 207 155 SAR (stock appreciation right) – Non Cash 0 0 0 0 852 93 85 104 71 Other Income^^ 15 98 -8 8 35 153 99 101 50 Forex Gain / (Loss) 100 193 -164 38 209 -241 341 -135 49 Reported EBITDA 2,751 2,632 2,659 3,119 2,184 3,165 4,362 3,832 3,560 Finance costs 471 483 468 429 374 297 302 298 274 Depreciation and amortisation 1,661 1,715 1,756 1,760 1,100 1,264 1,162 1,143 1,182 Profit Before Tax 619 434 435 929 710 1,604 2,898 2,390 2,104 Tax Expenses 194 84 -271 127 487 431 729 564 618 Reported Profit After Tax 425 350 706 802 223 1,173 2,169 1,826 1,486 EPS 0.10 0.08 0.16 0.19 0.05 0.25 0.46 0.39 0.32 Adjusted PAT 1,424 1,254 1,567 1,651 1,447 1,636 2,626 2,398 1,997 Adjusted PAT % 12.8% 11.5% 12.4% 12.9% 11.8% 12.3% 18.1% 15.3% 13.0% Adjusted EPS (Rs) 0.33 0.29 0.37 0.39 0.33 0.35 0.56 0.51 0.43 *Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), ^ Other expenses exclude forex loss. ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and show n separately. ** Adjusted EBITDA represents EBITDA adjusted for earnouts payable for acquisitions (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income / forex gain or loss).
Page 20
Thank You